

Figure S1. Representative cell cycle plots for Jurkat cells treated with Doxo or Eto for 24 or 72 h. C, control; Doxo, doxorubicin; Eto, etoposide.




Figure S2. Representative apoptosis data for Jurkat cells treated with Doxo or Eto for 24 or 72 h. (A) Annexin V/7-amino-actinomycin and (B) caspase-3/7 activity plots. C, control; Doxo, doxorubicin; Eto, etoposide.




Figure S3. Cell cycle and H2AX activation of Jurkat cells treated with low-dose Doxo or Eto for 72 h. (A) Representative cell cycle plots. (B) H2AX activation plots, showing levels of inactivated and activated H2AX. C, control; Doxo, doxorubicin; Eto, etoposide.




Figure S4. Representative cell cycle plots for Jurkat cells treated with Doxo or Eto with or without Wip1 knockdown. Doxo, doxorubicin; Eto, etoposide; C, control; Wip1, p53-induced phosphatase 1; siC, small interfering RNA control; siWip1, small interfering RNA targeting Wip1.




Figure S5. Representative apoptosis data for Jurkat cells treated with Doxo or Eto with or without Wip1 knockdown. (A) Annexin V/7-amino-actinomycin and (B) caspase-3/7 activity plots. Doxo, doxorubicin; Eto, etoposide; C, control; Wip1, p53-induced phosphatase 1; siC, small interfering RNA control; siWip1, small interfering RNA targeting Wip1.




Figure S6. Cell cycle and H2AX activation of Jurkat cells treated with Doxo or Eto with or without Wip1 knockdown. (A) Representative cell cycle plots. (B) H2AX activation plots, showing levels of inactivated and activated H2AX. Doxo, doxorubicin; Eto, etoposide; C, control; Wip1, p53-induced phosphatase 1; siC, small interfering RNA control; siWip1, small interfering RNA targeting Wip1.

